Q-omics provides the consensus-scored CASC2 profile across patient tissues and cancer cell-line models. CASC2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CASC2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CASC2 RNA expression shows 20,129 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where CASC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC2 survival associations across molecular data types. CASC2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC2 RNA expression–survival associations across cancer types. High CASC2 expression shows favorable associations in MESO, KIRC, BRCA, KIRP, PAAD and COAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CASC2 RNA expression.
This table summarizes CASC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CASC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC2 shows lower tumor expression in KICH, THCA, KIRC, LUSC, BLCA and LUAD. The KICH box plot shows higher CASC2 RNA expression in normal versus tumor tissue (log2 FC = −1.500, t-test p < 0.001).
This table shows molecular features associated with CASC2 in patient tissues and cancer cell lines. In patient samples, CASC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
